Featured Story

Google exec figures pharma could go viral on YouTube--if it tried

The champions of digital marketing pounded their chests in dismay earlier this month, when 2013 DTC-spending stats showed online ads on the wane. Down by 14%, and the numbers were pretty paltry to begin with. No wonder, then, that Google is lobbying the pharma business on YouTube's behalf.

Big Pharma sees danger, not safety, in FDA's new social media guidance

The FDA may have released its latest social media guidance in January, but judging by the industry's reaction, it appears some of pharma's marketers don't have any more answers than they did before. In fact, they have more questions.

Doc offices that nix free samples cut way back on branded scripts: JAMA study

For a study in JAMA Dermatology, researchers compared acne-drug prescriptions written at an academic medical center that doesn't allow free samples with scripts written by office-based dermatologists nationwide. Result? A huge difference in the rate of branded prescribing.

Lilly nabs FDA approval for its blockbuster cancer hopeful ramucirumab

Eli Lilly reached the FDA finish line with its cancer treatment Cyramza (ramucirumab), its star oncology candidate.

Newly minted GlaxoSmithKline diabetes drug faces formidable foes in GLP-1 market

GlaxoSmithKline's albiglutide, now dubbed Tanzeum for the U.S. market, nabbed FDA approval Tuesday. Now, the drug will go up against a triad of other GLP-1 treatments, including Novo Nordisk's powerhouse Victoza and AstraZeneca's exanatide franchise.